CN1458931A - 噻唑烷二酮衍生物的酒石酸盐 - Google Patents
噻唑烷二酮衍生物的酒石酸盐 Download PDFInfo
- Publication number
- CN1458931A CN1458931A CN01815685A CN01815685A CN1458931A CN 1458931 A CN1458931 A CN 1458931A CN 01815685 A CN01815685 A CN 01815685A CN 01815685 A CN01815685 A CN 01815685A CN 1458931 A CN1458931 A CN 1458931A
- Authority
- CN
- China
- Prior art keywords
- tartrate
- compound
- solvate
- consistent
- basically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003892 tartrate salts Chemical class 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 239000012453 solvate Substances 0.000 claims abstract description 29
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- -1 D (-) tartrate anion ion Chemical class 0.000 claims description 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 238000001237 Raman spectrum Methods 0.000 claims description 5
- 238000002329 infrared spectrum Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 229940095064 tartrate Drugs 0.000 description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000011928 denatured alcohol Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 150000001473 2,4-thiazolidinediones Chemical class 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 238000005079 FT-Raman Methods 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 229920004459 Kel-F® PCTFE Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical compound FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940095107 e.s.p. Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000000449 magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Abstract
一种新颖的药物化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化物,一种制备这种化合物的方法,一种包含这种化合物的药物组合物,以及这种化合物在医药方面的用途。
Description
本发明涉及新颖的药物,此药物的制法以及此药物在医学中的用途。
公开号为0306228的欧洲专利申请涉及一些据报导具有降低血糖和促使血清脂质减少的活性的噻唑烷二酮衍生物。EP0306228的实施例30的化合物是5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,3-二酮(以下称作“化合物(I)”)。
公开号为WO94/05659的国际专利申请披露了EP0306228的化合物的某些盐类,它们中的一种是酒石酸盐。WO94/05669的优选盐是马来酸盐。
现已发现,化合物(I)形成新颖的酒石酸盐(以下也称作“D(-)酒石酸盐”(“D(-)Tartrate”)),它是特别稳定的,因此适于大规模的制备和处理。此D(-)酒石酸盐还具有高熔点,和具有良好的总体流动性。因此此D(-)酒石酸盐令人惊异地能进行大规模药物加工特别是大规模研磨。
此新颖形式能够用有效的、经济的和特别适于大规模制备的可再生产工艺来制造。
此新颖的D(-)酒石酸盐还具有有用的药物性能,而且特别是人们已指出,它对糖尿病、与糖尿病相关的疾病以及它的并发症的治疗和/或预防是有用的。
因此,本发明提供5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化合物。
此D(-)酒石酸盐适用的是单酒石酸盐。
此单酒石酸盐还任选包括其他单价成盐离子例如碱金属阳离子或铵阳离子。
在一个优选方面,此D(-)酒石酸盐具有与图1基本上一致的红外光谱。
在一个优选方面,此D(-)酒石酸盐具有与图2基本上一致的拉曼光谱。
在一个优选方面,此D(-)酒石酸盐具有与表1或图3基本上一致的X-射线粉末衍射图(XRPD)。
在一个优选方面,此D(-)酒石酸盐具有与图4基本上一致的固态13CNMR谱。
在一个优选方面,此D(-)酒石酸盐的熔点在180-185℃的范围内,例如在180-183℃的范围内,如181.6℃。
在优选方面,本发明提供5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,3-二酮D(-)酒石酸盐,其特征在于它具有:
(i)基本上与图1一致的红外光谱;
(ii)基本上与图2一致的拉曼光谱;
(iii)基本上与表1或图3一致的X-射线粉末衍射图(XRPD);以及
(iv)基本上与图4一致的固态13CNMR谱。
本发明包括分离成纯形式的D(-)酒石酸盐或它的溶剂化物或与其他物质的混合物。因此,在一方面,本发明提供处于分离形式的D(-)酒石酸盐或它的溶剂化合物。
另一方面,本发明提供处于纯形式的D(-)酒石酸盐或它的溶剂化物。
在又一方面,本发明提供处于结晶形式的D(-)酒石酸盐或它的溶剂化物。
此外,本发明提供处于固体药物上可接受形式的D(-)酒石酸盐或它的溶剂化物,例如固体剂型,特别当用于口服时。
另外,本发明也提供处于药物上可接受形式的D(-)酒石酸盐或它的溶剂化物,特别是处于松散形式,这种形式特别易于进行研磨。
还有,本发明提供处于药物上可接受形式的D(-)酒石酸盐或它的溶剂化物,特别是处于松散形式,这种形式具有良好流动性,特别是良好的总体流动性。
适合的溶剂化物是水合物。
本发明也提供制备所述D(-)酒石酸盐或其溶剂化物的方法,其特征在于将优选分散于或溶解于合适溶剂中的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮化合物(I)或其盐,与酒石酸根离子源反应,然后,如果需要,制备所得的D(-)酒石酸盐的溶剂化物;以及回收此D(-)酒石酸盐或其溶剂化物。
适合的反应溶剂是烷醇如丙醇-2或乙醇,或烃如甲苯,酮如丙酮,酯如乙酸乙酯,醚如四氢呋喃,腈如乙腈,或卤代烃如二氯甲烷,或水,或有机酸如乙酸;或它们的混合物。
D(-)酒石酸根离子源可方便地是D(-)酒石酸。优选将D(-)酒石酸以固体加入或在溶液中加入,例如在水中或在低级醇如甲醇、乙醇或丙醇-2中,或在溶剂混合物中加入。D(-)酒石酸的适用可溶碱性盐如D(-)酒石酸铵,或者胺如乙胺或二乙胺的D(-)酒石酸盐,可被用作D(-)酒石酸根离子的替代源。
化合物(I)的浓度优选在2-25%重量/体积的范围内,更优选在5~2 0%的范围内。D(-)酒石酸溶液的浓度优选在5~130%重量/体积的范围内。
反应通常在室温或高温下进行,例如在溶剂的回流温度下进行,虽然也可以采用任何能生成所需产物的合适温度。
此D(-)酒石酸盐的溶剂化物例如水合物根据通常的方法制备。
所需化合物的回收通常包括从合适溶剂或溶剂混合物(方便的是从反应溶剂)中结晶出来,通常通过冷却予以促进。例如,此D(-)酒石酸盐可以从醇如丙醇-2或乙醇中结晶出来。通过蒸发出去部分或全部溶剂,或通过在高温下结晶随后控制冷却,任选分步进行,可以高产率地获得此盐。可以采用仔细控制沉淀温度的方法以改善产物的再生产率。
结晶也可以用D(-)酒石酸盐或其溶剂化物的结晶进行接种而开始,但这并不必需。
当此单酒石酸盐包括其他单价成盐离子如碱金属或铵阳离子时,通过将单酒石酸盐与所选择的单价成盐离子例如金属或铵离子的溶液反应而方便地形成该离子。作为代替,化合物(I)可以用该单价成盐离子的单酒石酸盐进行处理。
化合物(I)按照公知的方法制备,例如按照在EP0306228和WO94/05659中公开的那些方法制备。EP0306228和WO94/05659的公开在这里引用作参考文献。
D(-)酒石酸是商业提供的化合物。
当这里使用术语“T开始”时,它通常用差示扫描量热法测出,而且具有本技术领域都理解的意义,例如在Ford及Timmins,1989所著的《药物热分析,方法及应用》(Pharmaceutical Thermal Analysis,Techniques andApplications)中以“相应于前转变基线与外推的转变前沿的交叉点的温度”所表达的意义。
当这里就某些化合物而使用术语“良好的流动性能”时,它合适地表征为该化合物的Hausner比为小于或等于1.5,特别是小于或等于1.25。
“Hausner比”是本技术领域接受的术语。
当这里使用术语“与糖尿病相关的疾病的预防”时,它包括治疗那些疾病,如耐胰岛素性,受削弱的糖耐量,血内胰岛素过多症,及妊娠糖尿病。
糖尿病优选指II型糖尿病。
与糖尿病相关的疾病包括血糖过多及耐胰岛素性和肥胖症。此外,与糖尿病相关的疾病还包括高血压,心血管疾病特别是动脉粥样硬化,某些饮食疾病,特别是患与饮食不足相关的疾病如神经性食欲缺乏,及患与过食相关的疾病如肥胖症和厌食贪食症的患者的食欲调节和摄取量调节。与糖尿病相关的其他疾病还包括多囊卵巢综合症和甾体导致的耐胰岛素性。
这里包括的与糖尿病相关的疾病的并发症包括肾脏疾病,特别是与II型糖尿病发展相关的肾病,这包括糖尿病肾病变,肾小球性肾炎,肾小球硬化症,肾病综合症,高血压肾硬化,及最后阶段肾病。
如上所述,本发明的化合物具有有用的治疗性能:因此本发明提供了用作活性治疗物质的所述D(-)酒石酸盐或其溶剂化物。
更具体地说,本发明提供了用于治疗和/或预防糖尿病、与糖尿病相关的疾病以及其某些并发症的所述D(-)酒石酸盐或其溶剂化物。
此D(-)酒石酸盐或其溶剂化物本身即可给药,或者它优选以还包含药物上可接受的载体的药物组合物给药。配制此D(-)酒石酸盐或其溶剂化物的合适方法通常是在上述出版物中关于化合物(I)所公开的那些方法。
因此,本发明也提供一种包含所述D(-)酒石酸盐或其溶剂化物以及药物上可接受的载体的药物组合物。
此D(-)酒石酸盐或其溶剂化物一般以单位剂量形式给药。
此活性化合物可以以任何合适途径给药,但通常是经口或胃肠外途径给药。为了这种用法,此化合物通常与药物载体、稀释剂和/或赋形剂一起以药物组合物的形式使用,虽然此药物组合物的准确形式将自然取决于给药方式。
此组合物用混合制备,适用于口服、胃肠外或局部给药,为此制成片剂、胶囊,口服液体制剂,粉末、粒剂,锭剂,软锭剂,可再溶解的粉末,可注射的或可输注的溶液或悬浮液,栓剂和经皮使用的装置。口服组合物是优选的,特别是成形的口服组合物,因为它们更适合于普通用法。
口服的片剂或胶囊通常以单位剂量提供,并含有常用的赋形剂如粘结剂,填料,稀释剂,成片剂,润滑剂,崩解剂,着色剂,芳香剂,及润湿剂。这些片剂可以按本技术领域公知的方法包覆。
所用合适填料包括纤维素,甘露糖醇,乳糖及其他相似物。适用的崩解剂包括淀粉,聚乙烯吡咯烷酮及淀粉衍生物如淀粉乙醇酸钠。适用的润滑剂包括例如硬脂酸镁。适用的药物上可接受的润滑剂包括月桂基硫酸钠。
可以采用通常用的掺混、填充、压片等方法制造固体口服组合物。可以采用重复掺混的操作法把活性剂分散到使用了大量填料的组合物中。当然,这种操作在本技术领域是常用的。
口服液体制剂的形式可以是例如水悬浮液或油悬浮液,溶液,乳液,糖浆,或酏剂,或者它可以以干产物提供,这种干产物可以在使用前用水或其他合适媒介物进行再溶解。这种液体制剂可以含有常用添加剂例如悬浮剂如山梨醇、糖浆、甲基纤维素、明胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶或氢化食用脂,乳化剂如卵磷脂、脱水山梨醇单油酸酯或阿拉伯胶;非水媒介物(它可包括食用油)如杏仁油、分级椰子油、油性酯如甘油酯、丙二醇酯或乙醇酯;防腐剂如对羟基苯甲酸甲酯或丙酯、或山梨酸;而如果需要还可含通用的芳香剂或着色剂。
为了胃肠外给药,制备了含本发明化合物及无菌媒介物的液体单元剂量剂形式。根据媒介物及浓度,可将此化合物悬浮或溶解。胃肠外用的溶液通常通过将此活性化合物溶在媒介物中、在灌入合适小玻璃瓶或安瓿之前将过滤器消毒、以及封口而制取。将辅剂如局部麻醉剂、防腐剂及缓冲剂也溶于媒介物中也是有好处的。为提高稳定性,在灌入小玻璃瓶并在真空下除去水之后,可将此组合物冷冻。
胃肠外用的悬浮液用基本相同方法制备,只是将此活性化合物悬浮于媒介物中而不是使之溶解和在悬浮于消毒媒介物中之前曝露于环氧乙烷中使之消毒。在组合物中包括表面活性剂或润湿剂以使活性化合物均匀分布是有益的。
共同的做法是,在有关的药物疗法的使用中,此组合物通常伴有书写的或印刷的使用方法。
这里所用的术语“药物上可接受的”包括既可人用,也可兽用的化合物、组合物及各成分:例如术语“药物上可接受的盐”包括兽药上可接受的盐。
本发明还提供治疗和/或预防人或非人的哺乳动物的糖尿病、与糖尿病相关的疾病以及其某些并发症的方法,此方法包括给予需要的人或非人哺乳动物有效的无毒量的所述D(-)酒石酸盐或其溶剂化物。
此活性组份方便地以上面定义的药物组合物给药,这构成本发明的一个特别方面。
另一方面,本发明提供了此D(-)酒石酸盐及其溶剂化物在制造药物方面的用途,这种药物用于治疗和/或预防糖尿病、与糖尿病相关的疾病以及其某些并发症。
在治疗和/或预防糖尿病、与糖尿病相关的疾病以及其某些并发症时,所述D(-)酒石酸盐及其溶剂化物的使用量应使得能提供合适剂量的化合物(I),例如EP0306,228,WO94/05659或WO98/55122中所公开的。
对于本发明的化合物来说,在上述治疗中未发现有害的毒理作用。
下列实施例将解释本发明,但无论如何不是限制本发明。实施例1:5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐
将5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(2.0克),D(-)酒石酸(0.84克),丙酮(90毫升)及去离子水(5毫升)的混合物搅拌,并加热到70℃,生成清亮溶液。然后将此反应混合物冷至21℃,并在减压下除去溶剂。加入甲苯(50毫升),搅拌此混合物,并在减压下把溶剂蒸发掉。往残留物中加入乙酸乙酯(50毫升)及变性乙醇(20毫升)。搅拌此混合物并加热至回流,然后冷却至21℃。过滤收集产物,在真空下干燥,得到白色结晶固体5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐(1.2克)。
1HNMR(d6-DMSO):与5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐一致。实施例2:5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐
将5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(4.5克)与变性乙醇(120毫升)的混合物加热至回流,生成清亮溶液。把此溶液冷却至70℃,加入D-(-)-酒石酸(1.9克),并把此搅动中的混合物加热至回流。把此溶液冷却至45℃,用5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐的结晶进行引晶,并声处理5分钟,得到白色悬浮液。把此混合物冷却至21℃,过滤收集产物,用变性乙醇(20毫升)洗涤,并真空下干燥3小时,得到白色结晶固体5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐(5.8克)。实施例3:5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐
将5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(5.0克)与丙醇-2(100毫升)的混合物搅拌,加热至回流直至观察到清亮溶液为止。往反应混合物中加入60-70℃的D-(-)-酒石酸(2.1克)在丙醇-2(30毫升)中的溶液,然后在回流下搅拌5分钟。随后在90分钟内把此混合物冷至21℃。过滤收集产物,用丙醇-2(50毫升)洗涤,并在真空下干燥,得到白色结晶固体的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐(6.7克)。实施例4:5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐
将D-(-)-酒石酸(8.4克)在丙醇-2(70毫升)中的溶液在回流下加至搅拌下的5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮(20.0克)在丙醇-2(400毫升)中的悬浮液中。在回流下将此反应混合物搅拌,直至观察到一清亮溶液为止,然后冷却至21℃。过滤收集白色固体,用丙醇-2(100毫升)洗涤,然后在真空在21℃下干燥2小时,得到白色结晶固体5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D-(-)-酒石酸盐(26.9克)。
记录的实施例1产物的特征数据
用Nicolet710 FT-IR光谱仪在2cm-1分辨率下测得此产物在矿物油中的分散液的红外吸收光谱(图1)。以1cm-1间隔将这些数据进行数字化。在下列各处观察吸收谱带:3385,2792,1751,1700,1646,1621,1545,1512,1466,1416,1377,1357,1304,1267,1233,1217,1168,1153,1076,1060,1033;999,927,901,835,773,752,716,688,618,603,589,556,527,507cm-1。
用装有通用ATR附件的Perkin-Elmer Spectrum One FT-IR谱仪记录此固体产物的红外光谱。在下列各处观察吸收谱带:3384,2937,2787,1751,1694,1620,1609,1543,1511,1466,1415,1384,1357,1303,1267,1232,1217,1167,1153,1141,1075,1059,1032,998,927,899,832,772,751,715,686,658cm-1。
采用Nicolet 960 E.S.P.FT-Raman谱仪,在4cm-1分辨率下,用输出功率为400mw的Nd:V04激光仪(1064nm)激发,使用NMR管中的样品,记录下产物的拉曼光谱(图2)。在下列各处观察吸收谱带:3101,3065,3043,2920,1748,1700,1610,1584,1545,1471,1439,1390,1358,1320,1293,1236,1207,1177,1146,1060,1035,982,930,901,828,774,741,659,638,621,604,507,468,431,397,349,281,99.8cm-1。
采用下列捕获条件记录产物的X-射线衍射图(图3):管状阴极:CU,发生器电压:40Kv,发生器电流:40mA,起始角:20°2θ,终止角:35.0°2θ,步宽:0.02°2θ,每步时间:2.5秒。特征XRPD角及相对强度记录在表1中
表1
角 | 相对强度 |
2θ° | % |
6.4 | 10.2 |
7.9 | 11.6 |
9.7 | 3.6 |
10.6 | 4.3 |
12.2 | 11.9 |
12.8 | 10.4 |
13.1 | 7.9 |
14.1 | 7.3 |
14.7 | 4.9 |
15.8 | 22.9 |
16.5 | 100 |
17.5 | 29.7 |
17.9 | 11 |
18.2 | 13.4 |
18.6 | 36 |
19.4 | 29.3 |
21.3 | 21.4 |
21.6 | 24.3 |
22.6 | 75.9 |
23.7 | 15.8 |
24.3 | 49 |
25.2 | 34 |
25.7 | 43 |
26.4 | 14.3 |
27.2 | 28.6 |
27.4 | 22.3 |
28.3 | 15.1 |
29.2 | 29.6 |
29.6 | 8.7 |
30.4 | 9.4 |
30.7 | 14.3 |
31.1 | 14.9 |
31.6 | 13.6 |
32.1 | 12.4 |
33.3 | 15.2 |
33.8 | 16.6 |
将产物的固态NMR谱(图4)记录在于90.55MHz之下操作的BrukerAMX360仪上:将此固体装入安装有Kel-F盖子的4毫米氧化锆MAS转动体中,而转动体以约10KHz旋转。通过从Hartmann-Hahn匹配的质子的交叉极化(CP接触时间3毫秒,重复时间15秒)而获得13C MAS谱,而在用双脉冲相调制(TPPM)的复合程序进行的搜索过程中将质子去偶。将化学位移相对于TMS在176.4ppm处外部参比甘氨酸的羧酸根信号,在下列各处进行观察:181.2,179.0,177.4,174.7,173.0,158.2,156.9,150.3,145.6,144.7,141.9,139.3,136.1,131.7,126.6,118.1,113.7,111.0,110.0,75.2,74.6,73.7,73.0,64.6,56.6,55.7,50.8,47.4,40.6,38.8,36.7,34.8ppm。记录的实施例4的产物D(-)酒石酸盐的性能此D(-)酒石酸盐的固体稳定性:
此药物的固体稳定性通过在玻璃瓶中的大约1.0克此物质在下列情况下测定:a)在40℃/相对湿度(RH)75%,打开瓶子,1个月,b)在50℃,塞好瓶子,1个月。用HPLC测定在这两种情况下此物质的最终含量和降解产物。
a)40℃/75%RH:未观察到明显的降解(HPLC测出含起始物96%)。
b)50℃:未观察明显的降解(HPLC测出含起始物98%)。此D(-)酒石酸盐的流动性能:
用标准方法(见“药物-剂量形式设计的科学”(“Pharmaceutics-TheScience of Dosage Form Design”),编者M.Aulton,1988,由ChurchillLivingstone出版)测定此D(-)酒石酸盐的堆积密度与多头堆积密度(tapped bulkdensity)之间的比值(Hausner比)。
Hausner比;1.2此D(-)酒石酸盐的熔点
使用Buchi545熔点仪,按照美国药典,USP23,1995,<741>“熔点范围或温度,第Ia类方法”,测定此D(-)酒石酸盐的熔点。
熔点:181.6℃此D(-)酒石酸盐的T开始
用Perkin-Elmer DSC7仪器以差示扫描量热法测定此药物的T开始。
T开始(10℃/分钟,闭盘):187℃
Claims (11)
1.一种化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化物。
2.根据权利要求1的化合物,其特征在于它具有:
(i)基本上与图1一致的红外光谱;
(ii)基本上与图2一致的拉曼光谱;
(iii)基本上与表1或图3一致的X-射线粉末衍射图(XRPD);或
(iv)基本上与图4一致的固态13CNMR谱。
3.根据权利要求1的化合物,其特征在于它具有下列特征中的两个或更多个:
(i)基本上与图1一致的红外光谱;
(ii)基本上与图2一致的拉曼光谱;
(iii)基本上与表1或图3一致的X-射线粉末衍射图(XRPD);以及
(iv)基本上与图4一致的固态13CNMR谱。
4.根据权利要求1~3任一项的化合物,它处于已提纯形式。
5.根据权利要求1~3任一项的化合物,它处于固体剂量形式。
6.根据权利要求1~3任一项的化合物,它处于可被研磨的药物上可接受的形式。
7.根据权利要求1~3任一项的化合物,它处于具有良好流动性能的药物上可接受的形式。
8.一种制备上述的D(-)酒石酸盐或其溶剂化物的制法,其特征在于5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮或其盐与D(-)酒石酸根离子源反应,然后,如果需要,制备此D(-)酒石酸盐的溶剂化物;以及回收此D(-)酒石酸盐或其溶剂化物。
9.一种包含5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化物以及药物上可接受的载体的药物组合物。
10.一种用作活性治疗物质的化合物5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化物。
11.5-[4-[2-(N-甲基-N-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮D(-)酒石酸盐或其溶剂化物在制备于治疗和/或预防糖尿病、与糖尿病相关的疾病及其某些并发症的药物的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0019228.6 | 2000-08-04 | ||
GBGB0019228.6A GB0019228D0 (en) | 2000-08-04 | 2000-08-04 | Novel pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1458931A true CN1458931A (zh) | 2003-11-26 |
Family
ID=9897030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01815685A Pending CN1458931A (zh) | 2000-08-04 | 2001-08-03 | 噻唑烷二酮衍生物的酒石酸盐 |
Country Status (36)
Country | Link |
---|---|
US (1) | US20040048899A1 (zh) |
EP (1) | EP1305312B1 (zh) |
JP (1) | JP2004505972A (zh) |
KR (1) | KR100755173B1 (zh) |
CN (1) | CN1458931A (zh) |
AP (1) | AP1814A (zh) |
AT (1) | ATE393153T1 (zh) |
AU (1) | AU2001276509A1 (zh) |
BG (1) | BG107606A (zh) |
BR (1) | BR0112981A (zh) |
CA (1) | CA2417829A1 (zh) |
CZ (1) | CZ2003316A3 (zh) |
DE (1) | DE60133746T2 (zh) |
DK (1) | DK1305312T3 (zh) |
DZ (1) | DZ3467A1 (zh) |
EA (1) | EA004764B1 (zh) |
EC (1) | ECSP034469A (zh) |
ES (1) | ES2302506T3 (zh) |
GB (1) | GB0019228D0 (zh) |
HK (1) | HK1057359A1 (zh) |
HR (1) | HRP20030070A2 (zh) |
HU (1) | HUP0300777A3 (zh) |
IL (2) | IL154278A0 (zh) |
MA (1) | MA25898A1 (zh) |
MX (1) | MXPA03001087A (zh) |
NO (1) | NO324595B1 (zh) |
NZ (1) | NZ524032A (zh) |
OA (1) | OA12352A (zh) |
PL (1) | PL360703A1 (zh) |
PT (1) | PT1305312E (zh) |
SI (1) | SI1305312T1 (zh) |
SK (1) | SK1442003A3 (zh) |
UA (1) | UA76721C2 (zh) |
WO (1) | WO2002012234A1 (zh) |
YU (1) | YU16303A (zh) |
ZA (1) | ZA200300963B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39384E1 (en) | 1993-09-01 | 2006-11-07 | Smithkline Beecham P.L.C. | Substituted thiazolidinedione derivatives |
PE20051096A1 (es) * | 2004-02-04 | 2006-01-23 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida |
JP2008505075A (ja) * | 2004-06-30 | 2008-02-21 | イーライ リリー アンド カンパニー | 1−(インドール−6−カルボニル−d−フェニルグリシニル)−4−(1−メチルピペリジン−4−イル)ピペラジンd−酒石酸塩 |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
DE102009053562A1 (de) | 2009-11-18 | 2011-05-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung |
CN102532122B (zh) * | 2010-12-29 | 2015-12-02 | 开封制药(集团)有限公司 | 酒石酸罗格列酮的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288095B1 (en) * | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
DE3856378T2 (de) * | 1987-09-04 | 2000-05-11 | Beecham Group Plc | Substituierte Thiazolidindionderivate |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
-
2000
- 2000-08-04 GB GBGB0019228.6A patent/GB0019228D0/en not_active Ceased
-
2001
- 2001-03-08 UA UA2003020940A patent/UA76721C2/uk unknown
- 2001-08-03 SI SI200130830T patent/SI1305312T1/sl unknown
- 2001-08-03 SK SK144-2003A patent/SK1442003A3/sk unknown
- 2001-08-03 EA EA200300234A patent/EA004764B1/ru not_active IP Right Cessation
- 2001-08-03 KR KR1020037001606A patent/KR100755173B1/ko not_active IP Right Cessation
- 2001-08-03 PT PT01954162T patent/PT1305312E/pt unknown
- 2001-08-03 AP APAP/P/2003/002738A patent/AP1814A/en active
- 2001-08-03 NZ NZ524032A patent/NZ524032A/en unknown
- 2001-08-03 EP EP01954162A patent/EP1305312B1/en not_active Expired - Lifetime
- 2001-08-03 US US10/343,866 patent/US20040048899A1/en not_active Abandoned
- 2001-08-03 IL IL15427801A patent/IL154278A0/xx active IP Right Grant
- 2001-08-03 OA OA1200300026A patent/OA12352A/en unknown
- 2001-08-03 AT AT01954162T patent/ATE393153T1/de not_active IP Right Cessation
- 2001-08-03 HU HU0300777A patent/HUP0300777A3/hu unknown
- 2001-08-03 JP JP2002518209A patent/JP2004505972A/ja not_active Withdrawn
- 2001-08-03 ES ES01954162T patent/ES2302506T3/es not_active Expired - Lifetime
- 2001-08-03 YU YU16303A patent/YU16303A/sh unknown
- 2001-08-03 DE DE60133746T patent/DE60133746T2/de not_active Expired - Fee Related
- 2001-08-03 DZ DZ013467A patent/DZ3467A1/fr active
- 2001-08-03 CA CA002417829A patent/CA2417829A1/en not_active Abandoned
- 2001-08-03 PL PL36070301A patent/PL360703A1/xx not_active Application Discontinuation
- 2001-08-03 AU AU2001276509A patent/AU2001276509A1/en not_active Abandoned
- 2001-08-03 CN CN01815685A patent/CN1458931A/zh active Pending
- 2001-08-03 WO PCT/GB2001/003515 patent/WO2002012234A1/en active IP Right Grant
- 2001-08-03 BR BR0112981-3A patent/BR0112981A/pt not_active IP Right Cessation
- 2001-08-03 CZ CZ2003316A patent/CZ2003316A3/cs unknown
- 2001-08-03 MX MXPA03001087A patent/MXPA03001087A/es active IP Right Grant
- 2001-08-03 DK DK01954162T patent/DK1305312T3/da active
-
2003
- 2003-01-31 NO NO20030507A patent/NO324595B1/no not_active IP Right Cessation
- 2003-02-03 HR HR20030070A patent/HRP20030070A2/hr not_active Application Discontinuation
- 2003-02-03 MA MA27021A patent/MA25898A1/fr unknown
- 2003-02-03 IL IL154278A patent/IL154278A/en not_active IP Right Cessation
- 2003-02-04 EC EC2003004469A patent/ECSP034469A/es unknown
- 2003-02-28 BG BG107606A patent/BG107606A/bg unknown
- 2003-03-04 ZA ZA200300963A patent/ZA200300963B/en unknown
- 2003-10-24 HK HK03107710.1A patent/HK1057359A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1167702C (zh) | 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物 | |
CN1208335C (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
CN1426401A (zh) | 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途 | |
CN1285831A (zh) | 取代的噻唑烷二酮衍生物,其制备过程及其药学用途 | |
CN1152878C (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
CN1281453A (zh) | 作为药物的5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的水合物 | |
CN1458931A (zh) | 噻唑烷二酮衍生物的酒石酸盐 | |
CN1458930A (zh) | 噻唑烷二酮衍生物的酒石酸盐 | |
CN1443186A (zh) | 用于糖尿病治疗的噻唑烷二酮盐 | |
CN1366520A (zh) | 新型医药 | |
CN1239501C (zh) | 噻唑烷二酮衍生物以及其作为抗糖尿病药物的应用 | |
CN100345846C (zh) | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的钠盐 | |
CN1491224A (zh) | 5-[4-[2-(n-甲基-n-(2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮甲磺酸盐 | |
BG65428B1 (bg) | Тиазолидиндионово производно, метод за получаването му, фармацевтичен състав и използването му катоантидиабетик | |
CN1814599A (zh) | 一种噻唑烷二酮衍生物以及其作为抗糖尿病药的应用 | |
CN1612874A (zh) | 罗格列酮乙二磺酸盐和它们作为抗糖尿病药物的用途 | |
CN1455778A (zh) | 四氢噻唑二酮衍生物的酒石酸盐 | |
CN1443185A (zh) | 药用的5-(4-(2-(n-甲基-n-(2-吡啶基)氨基)乙氧基)苄基)噻唑烷-2,4-二酮氢碘化物 | |
CN1455777A (zh) | 四氢噻唑二酮衍生物的酒石酸盐 | |
CN1620453A (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
CN100390170C (zh) | 5-(4-(2-(n-甲基-n-(2-吡啶基)氨基)乙氧基)苄基)噻唑烷-2,4-二酮苯磺酸盐,它的制备方法,其多晶型物ⅰ、ⅱ和ⅲ和它作为药物活性成分的用途 | |
CN1471531A (zh) | 噻唑烷酮(thiazolidinone)硝酸盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20031126 |